Jahrling P B, Peters C J, Stephen E L
J Infect Dis. 1984 Mar;149(3):420-7. doi: 10.1093/infdis/149.3.420.
Lassa virus-infected cynomolgus monkeys were treated with Lassa virus-immune monkey serum containing a high concentration of neutralizing antibody, the antiviral drug ribavirin, or a combination of ribavirin plus immune serum at various times after infection. When treatment was initiated early (day 0 or 4), either ribavirin (30 mg/kg of body weight per day) or immune serum alone protected monkeys. However, when the initial treatment was delayed until day 7, only four of eight ribavirin-treated and only one of six serum-treated monkeys survived. Treatment with ribavirin combined with immune serum was more successful; all infected monkeys given combination treatment survived, including six treated initially on day 10. Increased doses of ribavirin given alone were toxic. The empirical observation that combined treatment with ribavirin plus serum results in enhanced survival in experimentally infected monkeys suggests that combined treatment might benefit human patients with Lassa fever as well.
将感染拉沙病毒的食蟹猴在感染后的不同时间，用含有高浓度中和抗体的拉沙病毒免疫猴血清、抗病毒药物利巴韦林或利巴韦林加免疫血清的组合进行治疗。当早期（第0天或第4天）开始治疗时，单独使用利巴韦林（每天30毫克/千克体重）或免疫血清均可保护猴子。然而，当初始治疗推迟到第7天时，接受利巴韦林治疗的8只猴子中只有4只存活，接受血清治疗的6只猴子中只有1只存活。利巴韦林与免疫血清联合治疗更为成功；接受联合治疗的所有感染猴子均存活，包括6只在第10天开始接受治疗的猴子。单独增加利巴韦林剂量有毒性。利巴韦林加血清联合治疗能提高实验感染猴子存活率这一经验性观察结果表明，联合治疗可能也会使拉沙热患者受益。
